Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) today announced that AZEDRA® (iobenguane I 131), the Company’s radiotherapeutic, has been added to the ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

FDA Management Comments

Progenics Announces Addition of AZEDRA® (iobenguane I 131) to National Comprehensive Cancer Network Guidelines for Pheochromocytoma and ParagangliomaSeptember 17, 2018 6:00 AM Progenics Pharmaceuticals (PGNX) Sell-Off 'Seems Overdone' - BTIGSeptember 13, 2018 11:53 AM Needham & Company Downgrades Progenics Pharmaceuticals (PGNX) to BuySeptember 13, 2018 11:30 AM Pre-Open Movers 09/13: (PI) (XBIT) (GNC) Higher; (PVTL) (PGNX) (FRED) Lower (more...)September 13, 2018 9:17 AM